Tenaya Therapeutics (TNYA) Competitors $1.24 +0.06 (+5.08%) Closing price 04:00 PM EasternExtended Trading$1.24 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. BGM, SANA, NRIX, ABUS, SNDL, OCS, GHRS, TBPH, PROK, and VIRShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include BGM Group (BGM), Sana Biotechnology (SANA), Nurix Therapeutics (NRIX), Arbutus Biopharma (ABUS), SNDL (SNDL), Oculis (OCS), GH Research (GHRS), Theravance Biopharma (TBPH), ProKidney (PROK), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors BGM Group Sana Biotechnology Nurix Therapeutics Arbutus Biopharma SNDL Oculis GH Research Theravance Biopharma ProKidney Vir Biotechnology Tenaya Therapeutics (NASDAQ:TNYA) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk. Does the media refer more to TNYA or BGM? In the previous week, Tenaya Therapeutics had 7 more articles in the media than BGM Group. MarketBeat recorded 7 mentions for Tenaya Therapeutics and 0 mentions for BGM Group. Tenaya Therapeutics' average media sentiment score of 0.50 beat BGM Group's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tenaya Therapeutics Positive BGM Group Neutral Do institutionals & insiders believe in TNYA or BGM? 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend TNYA or BGM? Tenaya Therapeutics presently has a consensus price target of $6.25, indicating a potential upside of 404.03%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenaya Therapeutics is more favorable than BGM Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00BGM Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, TNYA or BGM? Tenaya Therapeutics has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500. Comparatively, BGM Group has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Is TNYA or BGM more profitable? BGM Group's return on equity of 0.00% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -93.83% -75.66% BGM Group N/A N/A N/A Which has preferable valuation & earnings, TNYA or BGM? BGM Group has higher revenue and earnings than Tenaya Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$111.13M-$0.96-1.29BGM Group$25.10M28.70-$1.44MN/AN/A SummaryTenaya Therapeutics beats BGM Group on 7 of the 12 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.31M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-1.297.5859.1122.53Price / SalesN/A458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book1.169.9310.916.06Net Income-$111.13M-$53.38M$3.29B$266.28M7 Day Performance9.73%0.05%0.01%-0.76%1 Month Performance78.85%7.08%7.06%3.83%1 Year Performance-49.18%11.92%50.09%24.39% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics2.9553 of 5 stars$1.24+5.1%$6.25+404.0%-53.4%$192.31MN/A-1.29110Analyst ForecastBGMBGM GroupN/A$7.51-2.2%N/A-8.2%$730.14M$26.85M0.00298Positive NewsSANASana Biotechnology2.6407 of 5 stars$3.06+1.7%$8.00+161.4%-46.6%$727.70MN/A-2.89380NRIXNurix Therapeutics2.6347 of 5 stars$9.34-0.7%$28.87+209.1%-61.9%$714.03M$88.38M-3.58300News CoveragePositive NewsHigh Trading VolumeABUSArbutus Biopharma2.5964 of 5 stars$3.71+1.1%$5.50+48.2%-1.5%$711.21M$6.17M-12.7990News CoveragePositive NewsSNDLSNDL3.487 of 5 stars$2.68-0.4%$4.00+49.3%+27.9%$704.24M$944.25M-9.932,516News CoverageAnalyst ForecastOCSOculis2.5566 of 5 stars$16.13-1.3%$35.75+121.6%+35.7%$704.24M$780K-6.042Short Interest ↑GHRSGH Research2.2408 of 5 stars$13.50-2.5%$32.00+137.0%+42.9%$702.41MN/A-18.2410News CoverageTBPHTheravance Biopharma3.6468 of 5 stars$13.88-0.6%$21.33+53.7%+71.6%$699.00M$64.38M57.83110Positive NewsPROKProKidney3.3701 of 5 stars$2.36-5.6%$6.25+164.8%-1.7%$694.50M$80K-4.143News CoverageVIRVir Biotechnology3.2145 of 5 stars$4.94-2.0%$28.44+475.8%-29.2%$686.25M$14.39M-1.24580News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies BGM Group Competitors Sana Biotechnology Competitors Nurix Therapeutics Competitors Arbutus Biopharma Competitors SNDL Competitors Oculis Competitors GH Research Competitors Theravance Biopharma Competitors ProKidney Competitors Vir Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
